Zane Baird

BioMEMS Diagnostics is developing an ultrahigh performance Point of Care and at-home diagnostics platform featuring a simple, single-use test cartridge, handheld analyzer and smart device app to deliver results for complex tests previously available only in hospital or central lab settings. Up to ten different tests can be integrated into a single cartridge with results in less than 5 minutes. Test panels currently in development include respiratory infections, systemic inflammation, healthy aging, drug-resistant UTI, tropical diseases, recurrent myocardial infarction and concussion, many of which use a saliva or urine sample instead of a blood draw -- vastly increasing access to high-need, high-complexity testing at home or at Point of Care. The BioMEMS technology features a hybrid biosensor array that can be configured to accept a broad range of antibodies, aptamers, nucleic probes and other affinity agents, able to detect most any biomarker, ranging from a single pathogen to a single protein in most any biofluid. This is disruptive technology that also crushes the cost of manufacturing chip-based diagnostics by producing "blank" cartridges in the millions, and then adding the chemistry for specific diagnostics targets in a secondary operation, exponentially lowering costs. In so doing, BioMEMS vastly increases access to high-performance, high-complexity testing, offering an accurate, affordable testing platform with the potential to displace the current paradigm of collecting samples, transporting to a remote lab, and waiting for results when sophisticated tests are needed. No skill, no lab required. This proprietary, patent-pending, digital testing platform is equally effective in a doctors' office as it is in an ambulance, a combat zone or a tent hospital in South Sudan. A disruptive technology capable of transforming point-of-care. point-of-need and at home diagnostics.